BioCentury
ARTICLE | Company News

Amgen, Novartis enter risk-sharing CNS deal

September 2, 2015 1:38 AM UTC

Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) will collaborate to co-develop and co-commercialize candidates in Alzheimer's disease and migraine.

The companies said they will combine beta-site APP-cleaving enzyme (BACE) inhibitor programs to treat AD. Novartis' CNP520, which is in Phase I/IIa testing, will be the lead candidate. Amgen will make undisclosed upfront and milestone payments to Novartis, and pay "disproportional" R&D costs for an undisclosed time frame, after which the companies will share equally global profits and costs for all AD assets. ...